2VF0 Stock Overview
A clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hemostemix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.037 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.022 |
| Beta | 0.51 |
| 1 Month Change | 50.00% |
| 3 Month Change | -17.58% |
| 1 Year Change | -54.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -87.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VF0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 21.0% | -2.7% | -3.1% |
| 1Y | -54.3% | -24.2% | -0.5% |
Return vs Industry: 2VF0 underperformed the German Biotechs industry which returned -24.2% over the past year.
Return vs Market: 2VF0 underperformed the German Market which returned -0.5% over the past year.
Price Volatility
| 2VF0 volatility | |
|---|---|
| 2VF0 Average Weekly Movement | 32.3% |
| Biotechs Industry Average Movement | 4.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2VF0's share price has been volatile over the past 3 months.
Volatility Over Time: 2VF0's weekly volatility has increased from 20% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Thomas Smeenk | hemostemix.com |
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Hemostemix Inc. Fundamentals Summary
| 2VF0 fundamental statistics | |
|---|---|
| Market cap | €2.96m |
| Earnings (TTM) | -€1.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs 2VF0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VF0 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$1.70m |
| Earnings | -CA$1.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -57.0% |
How did 2VF0 perform over the long term?
See historical performance and comparison